Top

High Blood Pressure & Cardiovascular Prevention

Published in:

01-10-2020 | Echocardiography | Original article

Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Levels in Hypertensive Patients: Speckle Tracking Echocardiography

Authors: Ibtsam Khairat, Lamiaa Khedr, Rehab Werida

Published in: High Blood Pressure & Cardiovascular Prevention | Issue 5/2020

Abstract

Introduction

Structural and functional properties of the left ventricle (LV) wall have been reported to be altered in hypertension, even at early stages of the disease. Abnormal adipokine levels affect blood pressure regulation. Hypo-adiponectinaemia and hyper-leptinaemia were reported in hypertension.

Aim

To evaluate the effects of valsartan versus amlodipine on LV deformation also, on plasma adiponectin and leptin levels in hypertensive individuals.

Methods

LV strain was measured by two-dimensional speckle tracking echocardiography, plasma levels of adiponectin and leptin was determined in 30 healthy individuals served as control group and in 200 hypertensive patients before and after treatment for 6 months with either valsartan 160 mg or amlodipine 10 mg.

Results

Compared to control group longitudinal strain was significantly affected in hypertensive patients, adiponectin was significantly lower while TNF-α, hs-CRP and leptin levels were significantly higher in hypertensive group. A significant improvement in LV functions, along with a decrease in leptin and increase in adiponectin levels in valsartan group compared to amlodipine group.

Conclusions

Our results indicate that valsartan is superior to amlodipine when it comes to affecting the hormonal function of human adipose tissue. Valsartan has a beneficial effect on LV deformation and function presented in GLS.

Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev. 2000;5(2):67–73. https://doi.org/10.1023/A:1009884820941.CrossRef

Rusconi C, Sabatini T, Faggiano P, Ghizzoni G, Oneglia C, Simoncelli U, Gualeni A, Sorgato A, Marchetti A. Prevalence of isolated left ventricular diastolic dysfunction in hypertension as assessed by combined transmitral and pulmonary vein flow Doppler study. Am J Cardiol. 2001;87(3):357–60. https://doi.org/10.1016/s0002-9149(00)01378-3.CrossRefPubMed

García EH, Perna ER, Farías EF, Obregón RO, Macin SM, Parras JI, Agüero MA, Moratorio DA, Pitzus AE, Tassano EA, Rodriguez L. Reduced systolic performance by tissue Doppler in patients with preserved and abnormal ejection fraction: new insights in chronic heart failure. Int J Cardiol. 2006;108(2):181–8. https://doi.org/10.1016/j.ijcard.2005.04.026.CrossRefPubMed

Sanderson JE. Heart failure with a normal ejection fraction. Heart. 2007;93(2):155–8. https://doi.org/10.1136/hrt.2005.074187.CrossRefPubMed

Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, Zile MR, Voors AA, Lefkowitz MP, Packer M, McMurray JJ, Solomon SD, PARAMOUNT Investigators (2014) Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol 63(5):447–456. https://doi.org/10.1016/j.jacc.2013.09.052

Sabbatini AR, Fontana V, Laurent S, Moreno H. An update on the role of adipokines in arterial stiffness and hypertension. J Hypertens. 2015;33(3):435–44. https://doi.org/10.1097/HJH.0000000000000444.CrossRefPubMed

Fontana V, de Faria AP, Oliveira-Paula GH, Silva PS, Biagi C, Tanus-Santos JE, Moreno H. Effects of angiotensin-converting enzyme inhibition on leptin and adiponectin levels in essential hypertension. Basic Clin Pharmacol Toxicol. 2014;114(6):472–5. https://doi.org/10.1111/bcpt.12195.CrossRefPubMed

Kim DH, Kim C, Ding EL, Townsend MK, Lipsitz LA. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension. 2013;62(1):27–322. https://doi.org/10.1161/HYPERTENSIONAHA.113.01453.CrossRefPubMed

Scotece M, Conde J, López V, Lago F, Pino J, Gómez-Reino JJ, Gualillo O. Adiponectin and leptin: new targets in inflammation. Basic Clin Pharmacol Toxicol. 2014;114(1):97–102. https://doi.org/10.1111/bcpt.12109.CrossRefPubMed

10.

Galletti F, D'Elia L, Barba G, Siani A, Cappuccio FP, Farinaro E, Iacone R, Russo O, De Palma D, Ippolito R, Strazzullo P. High-circulating leptin levels are associated with greater risk of hypertension in men independently of body mass and insulin resistance: results of an eight-year follow-up study. J Clin Endocrinol Metab. 2008;93(10):3922–6. https://doi.org/10.1210/jc.2008-1280.CrossRefPubMed

11.

Singhal A, Farooqi IS, Cole TJ, O'Rahilly S, Fewtrell M, Kattenhorn M, Lucas A, Deanfield J. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation. 2002;106(15):1919–24. https://doi.org/10.1161/01.cir.0000033219.24717.52.CrossRefPubMed

12.

Rahmouni K, Morgan DA. Hypothalamic arcuate nucleus mediates the sympathetic and arterial pressure responses to leptin. Hypertension. 2007;49(3):647–52. https://doi.org/10.1161/01.HYP.0000254827.59792.b2.CrossRefPubMed

13.

Black HR, Bailey J, Zappe D, Samuel R. Valsartan: more than a decade of experience. Drugs. 2009;69(17):2393–414. https://doi.org/10.2165/11319460-000000000-00000.CrossRefPubMed

14.

Jeffers BW, Robbins J, Bhambri R, Wajsbrot D. A Systematic review on the efficacy of amlodipine in the treatment of patients with hypertension with concomitant diabetes mellitus and/or renal dysfunction, when compared with other classes of antihypertensive medication. Am J Ther. 2015;22(5):322–41. https://doi.org/10.1097/MJT.0000000000000202.CrossRefPubMed

15.

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7(2):79–108. https://doi.org/10.1016/j.euje.2005.12.014.CrossRefPubMed

16.

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39.e14. https://doi.org/10.1016/j.echo.2014.10.003.CrossRefPubMed

17.

Sun JP, Lee AP, Wu C, Lam YY, Hung MJ, Chen L, Hu Z, Fang F, Yang XS, Merlino JD, Yu CM. Quantification of left ventricular regional myocardial function using two-dimensional speckle tracking echocardiography in healthy volunteers–a multi-center study. Int J Cardiol. 2013;167(2):495–501. https://doi.org/10.1016/j.ijcard.2012.01.071.CrossRefPubMed

18.

Feigenbaum H, Mastouri R, Sawada S. A practical approach to using strain echocardiography to evaluate the left ventricle. Circ J. 2012;76(7):1550–5. https://doi.org/10.1253/circj.CJ-12-0665.CrossRefPubMed

19.

Dalen H, Thorstensen A, Aase SA, Ingul CB, Torp H, Vatten LJ, Stoylen A. Segmental and global longitudinal strain and strain rate based on echocardiography of 1266 healthy individuals: the HUNT study in Norway. Eur J Echocardiogr. 2010;11(12):176–83. https://doi.org/10.1093/ejechocard/jep194.CrossRefPubMed

20.

Wiesner G, Vaz M, Collier G, Seals D, Kaye D, Jennings G, Lambert G, Wilkinson D, Esler M. Leptin is released from the human brain: influence of adiposity and gender. J Clin Endocrinol Metab. 1999;84(7):2270–4. https://doi.org/10.1210/jcem.84.7.5854.CrossRefPubMed

21.

Tsao TS, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol. 2002;440(2–3):213–21. https://doi.org/10.1016/s0014-2999(02)01430-9.CrossRefPubMed

22.

Brouckaert P, Libert C, Everaerdt B, Takahashi N, Cauwels A, Fiers W. Tumor necrosis factor, its receptors and the connection with interleukin 1 and interleukin 6. Immunobiology. 1993;187(3–5):317–29. https://doi.org/10.1016/S0171-2985(11)80347-5.CrossRefPubMed

23.

Avci E, Cakir E, Cevher SC, Yaman H, Agilli M, Bilgi C. Determination of oxidative stress and cellular inflammation in patients with diabetic nephropathy and non-diabetic nephropathy being administered hemodialysis treatment due to chronic renal failure. Ren Fail. 2014;36(5):767–73. https://doi.org/10.3109/0886022X.2014.890841.CrossRefPubMed

24.

Delles C, Klingbeil AU, Schneider MP, Handrock R, Weidinger G, Schmieder RE. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens. 2003;16(12):1030–5. https://doi.org/10.1016/j.amjhyper.2003.07.017.CrossRefPubMed

25.

Fogari R, Derosa G, Zoppi A, Rinaldi A, Lazzari P, Fogari E, Mugellini A, Preti P. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res. 2005;28(3):209–14. https://doi.org/10.1291/hypres.28.209.CrossRefPubMed

26.

Ohashi K, Ouchi N, Matsuzawa Y. Adiponectin and hypertension. Am J Hypertens. 2011;24(3):263–9. https://doi.org/10.1038/ajh.2010.216.CrossRefPubMed

27.

Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, Fu Y, Motone M, Yamamoto K, Matsuo A, Ohashi K, Kihara S, Funahashi T, Rakugi H, Matsuzawa Y, Ogihara T. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43(6):1318–23. https://doi.org/10.1161/01.HYP.0000129281.03801.4b.CrossRefPubMed

28.

Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35(2):580–6. https://doi.org/10.1161/01.hyp.35.2.580.CrossRefPubMed

29.

Ayoub AM, Keddeas VW, Ali YA, El Okl RA. Subclinical LV dysfunction detection using speckle tracking echocardiography in hypertensive patients with preserved LV ejection fraction. Clin Med Insights Cardiol. 2016;27(10):85–90. https://doi.org/10.4137/CMC.S38407.CrossRef

30.

Tadic M, Majstorovic A, Pencic B, Ivanovic B, Neskovic A, Badano L, Stanisavljevic D, Scepanovic R, Stevanovic P, Celic V. The impact of high-normal blood pressure on left ventricular mechanics: a three-dimensional and speckle tracking echocardiography study. Int J Cardiovasc Imaging. 2014;30(4):699–711. https://doi.org/10.1007/s10554-014-0382-3.CrossRefPubMed

31.

Kim SA, Park SM, Kim MN, Shim WJ. Assessment of left ventricular function by layer-specific strain and its relationship to structural remodelling in patients with hypertension. Can J Cardiol. 2016;32(2):211–6. https://doi.org/10.1016/j.cjca.2015.04.025.CrossRefPubMed

32.

Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyileten T, Acikel C, Oguz Y, Yavuz I, Vural A. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton). 2007;12(2):147–53. https://doi.org/10.1111/j.1440-1797.2007.00764.x.CrossRef

33.

Ohbayashi H, Minatoguchi S, Aoyama T, Fujiwara H. Open-label, randomized crossover study between telmisartan and valsartan on improving insulin resistance and adipocytokines in nondiabetic patients with mild hypertension. J Rural Med. 2010;5(2):165–74. https://doi.org/10.2185/jrm.5.165.CrossRefPubMedPubMedCentral

34.

Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110(9):1103–7. https://doi.org/10.1161/01.CIR.0000140265.21608.8E.CrossRefPubMed

35.

Pscherer S, Heemann U, Frank H. Effect of Renin-Angiotensin system blockade on insulin resistance and inflammatory parameters in patients with impaired glucose tolerance. Diabetes Care. 2010;33(4):914–9. https://doi.org/10.2337/dc09-1381.CrossRefPubMedPubMedCentral

36.

Aksnes TA, Seljeflot I, Torjesen PA, Hoieggen A, Moan A, Kjeldsen SE. Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity. Metabolism. 2007;56(11):1470–7. https://doi.org/10.1016/j.metabol.2007.06.012.CrossRefPubMed

37.

Goossens GH, Moors CC, van der Zijl NJ, Venteclef N, Alili R, Jocken JW, Essers Y, Cleutjens JP, Clément K, Diamant M, Blaak EE. Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trial. PLoS ONE. 2012;7(6):e39930. https://doi.org/10.1371/journal.pone.0039930.CrossRefPubMedPubMedCentral

38.

Watanabe S, Okura T, Kurata M, Irita J, Manabe S, Miyoshi K, Fukuoka T, Murakami K, Higaki J. The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. Clin Ther. 2006;28(10):1677–85. https://doi.org/10.1016/j.clinthera.2006.10.012.CrossRefPubMed

39.

Özkan B, Açar G, Alıcı G, Alizade E, Tabakcı MM, Sahin M, Yazıcıoğlu MV, Ozkok A, Tanboğa IH, Coşkun C, Esen AM. Decreased plasma adiponectin is associated with impaired left ventricular longitudinal systolic function in hypertensive patients: a two-dimensional speckle tracking study. Clin Exp Hypertens. 2014;36(1):46–51. https://doi.org/10.3109/10641963.2013.783053.CrossRefPubMed

40.

Vitlyanova K, Naidenov S, Runev N, Manov E, Shabani R, Rangelov Y, Koshtikova K, Donova T. Effects of the angiotensin receptor blocker Valsartan (Valsacor®) on arterial pressure, indices of myocardial diastolic function and global longitudinal strain in patients with uncontrolled arterial hypertension. Vnitr Lek. 2013;59(12):1124–8 (PMID: 24466609).PubMed

41.

Yamamoto K, Mano T, Yoshida J, Sakata Y, Nishikawa N, Nishio M, Ohtani T, Hori M, Miwa T, Masuyama T. ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure. J Hypertens. 2005;23(2):393–400. https://doi.org/10.1097/00004872-200502000-00022.CrossRefPubMed

42.

Uziębło-Życzkowska B, Krzesiński P, Gielerak G, Skrobowski A. Speckle tracking echocardiography and tissue Doppler imaging reveal beneficial effect of pharmacotherapy in hypertensives with asymptomatic left ventricular dysfunction. J Am Soc Hypertens. 2017;11(6):334–42. https://doi.org/10.1016/j.jash.2017.03.009.CrossRefPubMed

43.

Tzortzis S, Ikonomidis I, Triantafyllidi H, Trivilou P, Pavlidis G, Katsanos S, Katogiannis K, Birba D, Thymis J, Makavos G, Varoudi M, Frogoudaki A, Vrettou AR, Vlastos D, Parissis J, Lekakis J. Optimal blood pressure control improves left ventricular torsional deformation and vascular function in newly diagnosed hypertensives: a 3-year follow-up study. J Cardiovasc Transl Res. 2020. https://doi.org/10.1007/s12265-019-09951-9.CrossRefPubMed

44.

Kucukler N, Kurt IH, Topaloglu C, Gurbuz S, Yalcin F. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Med (Hagerstown). 2012;13(3):181–6. https://doi.org/10.2459/JCM.0b013e3283511f00.CrossRef

45.

Motoki H, Koyama J, Izawa A, Tomita T, Miyashita Y, Takahashi M, Ikeda U. Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy. Echocardiography. 2014;31(10):1230–8. https://doi.org/10.1111/echo.12548.CrossRefPubMed

46.

Bamaiyi AJ, Norton GR, Peterson V, Libhaber CD, Sareli P, Woodiwiss AJ. Limited contribution of left ventricular mass and remodelling to the impact of blood pressure on diastolic function in a community sample. J Hypertens. 2019;37(6):1191–9. https://doi.org/10.1097/HJH.0000000000002051.CrossRefPubMed

47.

Tadic M, Cuspidi C. The effect of antihypertensive therapy on left ventricular longitudinal strain: missing part of the puzzle. J Cardiovasc Transl Res. 2020. https://doi.org/10.1007/s12265-020-09970-x.CrossRefPubMed

Title: Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Levels in Hypertensive Patients: Speckle Tracking Echocardiography
Authors: Ibtsam Khairat
Lamiaa Khedr
Rehab Werida
Publication date: 01-10-2020
Publisher: Springer International Publishing
Keywords: Echocardiography
Amlodipine
Echocardiography
Valsartan
Hypertension
Hypertension
Published in: High Blood Pressure & Cardiovascular Prevention / Issue 5/2020
Print ISSN: 1120-9879
Electronic ISSN: 1179-1985
DOI: https://doi.org/10.1007/s40292-020-00398-7

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Levels in Hypertensive Patients: Speckle Tracking Echocardiography

Abstract

Introduction

Aim

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Aim

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2020

Assessing Atrial Fibrillation Substrates by P Wave Analysis: A Comprehensive Review

Abstracts from 2020 national congress of the Italian Society of Hypertension (SIIA)

Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice

Blood Pressure, Congestion and Heart Failure with Preserved Ejection Fraction Among Patients with and Without Type 2 Diabetes Mellitus. A Cluster Analysis Approach from the Observational Registry DICUMAP

New Mechanisms of Vascular Dysfunction in Cardiometabolic Patients: Focus on Epigenetics

Are Unattended Blood Pressure Measurements Necessary in All Patients Visiting an Outpatient Cardiology Clinic?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page